TLSA

Tiziana Life Sciences Ltd

0.60 USD

Last updated Dec 6, 17:29 UTC

Yesterday HIGH

$0.62

Yesterday LOW

$0.59

52w HIGH

$1.39

52w LOW

$0.5

EPS

-0.15

PE

-3.97

Next Earnings

Dec 26, 2023

Overview News Government Trades

Tiziana Life Sciences Ltd stock is down -3.89% since 30 days ago. The next earnings date is Dec 26, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November.

Tiziana Life Sciences plc focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

tizianalifesciences.com

Benzinga Newsdesk

Mon Jun 5, 2023

Tiziana Life Sciences Announces Reduction In Microglial Activation In A Total Of 5 Out Of 6 Intranasal Foralumab Expanded Access Patients With Non-Active Secondary Progressive Multiple Sclerosis
Happy Mohamed

Wed Apr 26, 2023

Tiziana Life Sciences Ltd Reports Annual Results For The 12 Months Ended December 31, 2022, And Corporate Update; Tiziana Ended The Period With $18.1M Cash

2022 Year End Financial Results For the twelve months ended 31 December 2022 Tiziana reported a loss of $19.0 million compared to $27.9 million in the twelve months ended 31 December
Lisa Levin

Tue Apr 25, 2023

Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers
Benzinga Newsdesk

Thu Apr 20, 2023

Tiziana Life Sciences To File Alzheimer's IND For Intranasal Foralumab In Q2 2023
Benzinga Newsdesk

Tue Apr 18, 2023

Tiziana Life Sciences Initiates Program To Develop Intranasal Foralumab For Treatment Or Prevention Of Type 1 Diabetes
Benzinga Newsdesk

Thu Apr 13, 2023

EXCLUSIVE: Tiziana Life Sciences Tells Benzinga 'Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillion'
Vandana Singh

Thu Apr 13, 2023

EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients

Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia cells, a key component in this disease's pathogenesis.
Benzinga Newsdesk

Thu Apr 13, 2023

EXCLUSIVE: Tiziana Life Sciences Tells Benzinga Co To Pursue Development Of Intranasal Foralumab For The Treatment Of Long COVID
Benzinga Newsdesk

Mon Apr 10, 2023

Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the "Preserving the Brain" Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

Tiziana Life Sciences Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today
Happy Mohamed

Tue Apr 4, 2023

Tiziana Life Sciences Announces Invitation For Podium Presentation Of Research On Intranasal Anti-CD3 mAb In Intracerebral Hemorrhage At The Annual American Academy Of Neurology Conference

Dr. Saef Izzy's data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial

AFRM $41.52 USD

BOIL $30.53 USD

MDB $403.76 USD

BRLI BRLI $11.55 USD

ASAN $20.01 USD

PYPL $60.31 USD

MARA $16.09 USD